|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maida M, Macaluso FS, Ianiro G, Mangiola
F, Sinagra E, Hold G, Maida C, Cammarota G, Gasbarrini A and
Scarpulla G: Screening of colorectal cancer: Present and future.
Expert Rev Anticancer Ther. 17:1131–1146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Binefa G, Rodriguez-Moranta F, Teule A and
Medina-Hayas M: Colorectal cancer: From prevention to personalized
medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tapia Rico G, Townsend AR, Broadbridge V
and Price TJ: Targeted therapies in elderly patients with
metastatic colorectal cancer: A review of the evidence. Drugs
Aging. 34:173–189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Passardi A, Canale M, Valgiusti M and
Ulivi P: Immune checkpoints as a target for colorectal cancer
treatment. Int J Mol Sci. 18:E13242017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T,
Wang Q and Jiang J: PD-1 and PD-L1 co-expression predicts favorable
prognosis in gastric cancer. Oncotarget. 8:64066–64082. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song P, Cui X, Bai L, Zhou X, Zhu X, Zhang
J, Jin F, Zhao J, Zhou C, Zhou Y, et al: Molecular characterization
of clinical responses to PD-1/PD-L1 inhibitors in non-small cell
lung cancer: Predictive value of multidimensional immunomarker
detection for the efficacy of PD-1 inhibitors in Chinese patients.
Thorac Cancer. 10:1303–1309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li S, Chen L and Jiang J: Role of
programmed cell death ligand-1 expression on prognostic and overall
survival of breast cancer: A systematic review and meta-analysis.
Medicine (Baltimore). 98:e152012019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, He M, Zhou Y, Yang C, Wei S, Bian X,
Christopher O and Xie L: The prognostic and clinicopathological
roles of PD-L1 expression in colorectal cancer: A systematic review
and meta-analysis. Front Pharmacol. 10:1392019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yaghoubi N, Soltani A, Ghazvini K,
Hassanian SM and Hashemy SI: PD-1/PD-L1 blockade as a novel
treatment for colorectal cancer. Biomed Pharmacother. 110:312–318.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ng HY, Li J, Tao L, Lam AK, Chan KW, Ko
JMY, Yu VZ, Wong M, Li B and Lung ML: Chemotherapeutic treatments
increase PD-L1 expression in esophageal squamous cell carcinoma
through EGFR/ERK activation. Transl Oncol. 11:1323–1333. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mimura K, Teh JL, Okayama H, Shiraishi K,
Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, et al:
PD-L1 expression is mainly regulated by interferon gamma associated
with JAK-STAT pathway in gastric cancer. Cancer Sci. 109:43–53.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin X, Liu C, Zhou Y and Wang G: Cisplatin
induces programmed death-1-ligand 1(PD-L1) over-expression in
hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol
(Noisy-le-grand). 11:OL1366–OL1372. 2010.
|
|
15
|
Bellucci R, Martin A, Bommarito D, Wang K,
Hansen SH, Freeman GJ and Ritz J: Interferon-γ-induced activation
of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells
through upregulation of PD-L1 expression. Oncoimmunology.
4:e10088242015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Imai D, Yoshizumi T, Okano S, Itoh S,
Ikegami T, Harada N, Aishima S, Oda Y and Maehara Y: IFN-γ promotes
epithelial-mesenchymal transition and the expression of PD-L1 in
pancreatic cancer. J Surg Res. 240:115–123. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cuccurullo V and Mansi L: AJCC Cancer
staging Handbook: From the AJCC cancer staging manual (7th
edition). Eur J Nucl Med Mol Imaging. 38:408. 2011. View Article : Google Scholar
|
|
19
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu H, Qin H, Huang Z, Li S, Zhu X, He J,
Yang J, Yu X and Yi X: Clinical significance of programmed death
ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. Int J Clin
Exp Pathol. 8:9351–9359. 2015.PubMed/NCBI
|
|
25
|
Enkhbat T, Nishi M, Takasu C, Yoshikawa K,
Jun H, Tokunaga T, Kashihara H, Ishikawa D and Shimada M:
Programmed cell death ligand 1 expression is an independent
prognostic factor in colorectal cancer. Anticancer Res.
38:3367–3373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu R, Peng K, Yu Y, Liang L, Xu X, Li W,
Yu S and Liu T: Prognostic value of immunoscore and PD-L1
expression in metastatic colorectal cancer patients with different
RAS status after palliative operation. Biomed Res Int.
2018:59206082018.PubMed/NCBI
|
|
27
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carretero-Gonzalez A, Lora D, Ghanem I,
Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA,
Paz-Ares L and de Velasco G: Analysis of response rate with ANTI
PD1/PD-L1 monoclonal antibodies in advanced solid tumors: A
meta-analysis of randomized clinical trials. Oncotarget.
9:8706–8715. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Asaoka Y, Ijichi H and Koike K: PD-1
Blockade in tumors with mismatch-repair deficiency. N Engl J Med.
373:19792015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
O'Neil BH, Wallmark J, Lorente D, Elez E,
Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Moss RA, Siu LL,
et al: Pembrolizumab (MK-3475) for patients (pts) with advanced
colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028.
Eur J Cancer. 51:4332015. View Article : Google Scholar
|
|
31
|
Concha-Benavente F, Srivastava RM, Trivedi
S, Lei Y, Chandran U, Seethala RR, Freeman GJ and Ferris RL:
Identification of the cell-intrinsic and -extrinsic pathways
downstream of EGFR and IFNγ that induce PD-L1 expression in head
and neck cancer. Cancer Res. 76:1031–1043. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, Liang L, Dai W, Cai G, Xu Y, Li X,
Li Q and Cai S: Prognostic impact of programed cell death-1 (PD-1)
and PD-ligand 1 (PD-L1) expression in cancer cells and tumor
infiltrating lymphocytes in colorectal cancer. Mol Cancer.
15:552016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kong P, Wang J, Song Z, Liu S, He W, Jiang
C, Xie Q, Yang L, Xia X and Xia L: Circulating lymphocytes, PD-L1
expression on tumor-infiltrating lymphocytes, and survival of
colorectal cancer patients with different mismatch repair gene
status. J Cancer. 10:1745–1754. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Calik I, Calik M, Turken G, Ozercan IH,
Dagli AF, Artas G and Sarikaya B: Intratumoral cytotoxic
T-lymphocyte density and PD-L1 expression are prognostic biomarkers
for patients with colorectal cancer. Medicina (Kaunas).
55:E7232019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sudoyo AW, Kurniawan AN, Kusumo GD, Putra
TP, Rexana FA, Yunus M, Budiyati AD, Kurniawan D, Utama A and Utomo
AR: Increased CD8 tumor infiltrating lymphocytes in colorectal
cancer microenvironment supports an adaptive immune resistance
mechanism of PD-L1 expression. Asian Pac J Cancer Prev.
20:3421–3427. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meyer SC: Mechanisms of resistance to JAK2
inhibitors in myeloproliferative neoplasms. Hematol Oncol Clin
North Am. 31:627–642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gotthardt D, Putz EM, Grundschober E,
Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z,
Witalisz-Siepracka A, Cumaraswamy AA, et al: STAT5 is a key
regulator in NK cells and acts as a molecular switch from tumor
surveillance to tumor promotion. Cancer Discov. 6:414–429. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Valentini AM, Di Pinto F, Cariola F,
Guerra V, Giannelli G, Caruso ML and Pirrelli M: PD-L1 expression
in colorectal cancer defines three subsets of tumor immune
microenvironments. Oncotarget. 9:8584–8596. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oliveira AF, Bretes L and Furtado I:
Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal
cancer. Front Oncol. 9:3962019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Angell HK, Lee J, Kim KM, Kim K, Kim ST,
Park SH, Kang WK, Sharpe A, Ogden J, Davenport A, et al: PD-L1 and
immune infiltrates are differentially expressed in distinct
subgroups of gastric cancer. Oncoimmunology. 8:e15444422019.
View Article : Google Scholar : PubMed/NCBI
|
